Management of Bone Health in Breast Cancer Survivors
JCO Oncology Practice · 10.06.2026
DOI: 10.1200/op-26-00169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, online erschienen am 10.06.2026. Verfasst von Kumar Shivam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT. Die Arbeit nennt 79 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Breast cancer survivors (BCS) face a significantly higher risk of treatment-induced bone loss compared with the general population. Despite clinical guidelines, baseline bone mineral density (BMD) screening and indicated pharmacologic interventions remain consistently underutilized in this population. DESIGN This review synthesizes current evidence regarding the pathophysiology and incidence of bone loss in BCS. We evaluate the impact of cytotoxic and endocrine therapies on skeletal health and summarize contemporary guidelines for the screening, prevention, and management of cancer treatment-induced bone loss. RESULTS Up to 80% of patients with breast cancer experience bone loss during treatment, primarily driven by iatrogenic estrogen depletion. Fewer than half of patients starting endocrine therapy with aromatase inhibitors receive a baseline dual-energy x-ray absorptiometry scan as recommended by ASCO guidelines, and nearly 50% of treatment-eligible patients remain untreated. Proactive mitigation is essential and must include baseline BMD screening and fracture risk assessment (FRAX) at the initiation of endocrine therapy, with interval monitoring frequency that is tailored by baseline risk. In patients with osteoporosis or high-risk osteopenia, antiresorptive agents effectively improve BMD and reduce fracture-associated morbidity and mortality. A multipronged approach incorporating lifestyle factors such as calcium/vitamin D supplementation, smoking cessation, and weight-bearing exercise is critical for optimizing long-term skeletal health. CONCLUSION Bone loss is a nearly universal consequence of breast cancer therapy. Integrating proactive BMD monitoring, standardized FRAX, and timely initiation of antiresorptive therapy into survivorship care is vital to improve long-term outcomes and functional independence in BCS.
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT.
- Department of Internal Medicine, University of Utah, Salt Lake City, UT.
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
- Division of Endocrinology, Department of Internal Medicine, University of Utah, Salt Lake City, UT.
- Division of Oncology, Department of Internal Medicine, University of Utah, Salt Lake City, UT.
ORCID-Profile: Jessica Allen, Faisal Aljabrain, Jairam Krishnamurthy, Kristen C Kelley
Zitieren
APA
Shivam, K., Allen, J., Aljabrain, F., Elliott, K. P., Krishnamurthy, J., & Kelley, K. C. (2026). Management of Bone Health in Breast Cancer Survivors. JCO Oncology Practice. https://doi.org/10.1200/op-26-00169
Vancouver
Shivam K, Allen J, Aljabrain F, Elliott KP, Krishnamurthy J, Kelley KC. Management of Bone Health in Breast Cancer Survivors. JCO Oncology Practice. 2026. doi:10.1200/op-26-00169
BibTeX
@article{Shivam2026,
author = {Shivam, Kumar and Allen, Jessica and Aljabrain, Faisal and Elliott, Karma-Jaya P and Krishnamurthy, Jairam and Kelley, Kristen C},
title = {Management of Bone Health in Breast Cancer Survivors},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-26-00169}
}
EUVIMED